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Summary Steroids and adrenocorticotrophic hormone (ACTH) have been used for
the treatment of infantile spasms for several years. However, the use of steroids in the
treatment of epilepsy beyond infantile spasms has been limited to only a few studies.
We report the experience with steroids in 32 children with intractable epilepsy, not
including West syndrome. In 47% there was a decrease in seizure frequency, 25%
became seizure free, 11% had a seizure reduction of >50% and 11% had a seizure
reduction of <50%. Our study confirms the conclusions of few previous reports of
effective adjunctive steroid treatment for children with intractable epilepsy. The
possible side effects, however, especially during prolonged therapy remain an impor-
tant concern.
# 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
The treatment of epilepsy can be a very frustrating
task. About 25% of epilepsy patients are refractory
to all classical anti-epileptic drugs. William G. Len-
nox reported in 1928 ‘‘One who is confronted with* Corresponding author. Tel.: +32 92 40 35 91;
ax: +32 92 40 38 75.
E-mail address: helene.verhelst@ugent.be (H. Verhelst).
1 Members of the Flemish Circle of Epilepsy.
2 Beyond the first author, all authors contribute equally.
059-1311/$ — see front matter # 2005 BEA Trading Ltd. Published
oi:10.1016/j.seizure.2005.07.002the task of controlling seizures in a person with
epilepsy grasps at any straw’’. In that context many
alternative treatments have been used in former
days from powdered human skull, to gall bladder of
a boar dried with urine, or blood or liver of a
recently slain gladiator. Currently, beside classical
anti-epileptic drugs, some less conventional thera-
pies are utilized in the treatment of intractable
seizures, as there are ketogenic diet, immunoglo-
bulins, steroids and vagus nerve stimulation.1
Adrenocorticotrophic hormone (ACTH) was first
reported to have beneficial effects in the treatmentby Elsevier Ltd. All rights reserved.
Steroids in childhood epilepsy 413of children with intractable seizures in 1950.2 Eight
years later, its specific therapeutic activity in infan-
tile spasms was described.3 Subsequently numerous
reports demonstrated the effect of ACTH or steroids
in West syndrome. Since the mechanism of action of
ACTH or steroids in infantile spasms is unknown, it is
controversial whether ACTH is superior to glucocor-
ticoids or not. Some studies have reported that
ACTH and prednisone have similar efficacy,4,5
whereas others have found ACTH to be more effec-
tive.6,7 A recent review of the treatment of infantile
spasms concluded that ACTH and vigabatrine were
most effective in infantile spasms but that there was
concern about the safety-profile.8
Apart from West syndrome, there are few reports
about the use of steroids in children with intractable
epilepsy. We report the experience with oral ster-
oids or intramuscular ACTH for the treatment of
children with intractable epilepsy, excluding chil-
dren with West syndrome.Methods
A retrospective assessment was made of all pedia-
tric patients who were treated with steroids for
intractable epilepsy at the Ghent University Hospi-
tal, Epilepsy and Rehabilitation Center Pulderbos
and the Academic Hospital of Brussels between 1993
and 2003. Patients with West syndrome and patients
who received a single dose for status epilepticus
were excluded.
A total of 32 patients (16 boys, 16 girls) were
included, of which 3 patients had two to three
courses of treatment with steroids. All patients
had failed first and second line anti-epileptic med-
ication. Patient’s medical charts were studied. Gen-
der, age at onset epilepsy, age at start of treatment,
seizure type, seizure frequency, EEG and MRI
abnormalities, mental status, etiology, previous
anti-epileptic drugs and type, dose and duration
of steroid therapy, effect of steroid therapy on
seizure frequency, EEG and cognition, and side
effects were registered. Duration of follow-up was
between 6 months and 8 years with a mean follow-
up period of 36 months.Results
Patient’s characteristics are listed in Table 1. Thirty-
two patients (16 males/16 females) were included.
Mean age at onset epilepsy was 2.6 year (males 1.5/
females 3.7) and mean age at treatment with ster-
oids was 4.7 year (males 3.8/females 5.7). Prior to
steroid treatment, all patients received 2—10 dif-ferent anti-epileptic drugs. Most patients had fre-
quent seizures with 21 patients having at least one
seizure a day and 6 others having at least one seizure
a week. In one patient, overt seizures were not
noticed and because of sub-coma, change of con-
sciousness could not be appreciated while the EEG
was strongly indicative of an ictal event. In the
entire group, the seizure types were very diverse
including absences, atypical absences, tonic, clo-
nic, tonic—clonic, myoclonic, atonic, simple partial,
complex partial and secondary generalized seizures.
All patients had epileptiform abnormalities in the
EEG records. MRI was normal in 14 and abnormal in
17 patients of which 11 had post-ischemic, post-
infection or post-hemorrhagic lesions. In one
patient, MRI results were not available. Other etio-
logic diagnoses are trisomy 21, ceroid lipofuscinosis,
Alpers disease, pyridoxine-dependent seizures,
hemimegalencephaly, Landau—Kleffner syndrome
(LKS) and electrical status epilepticus in sleep
(ESES). At the time of treatment all patients were
mentally retarded. Six patients were initially men-
tally normal but regressed. Of the remaining 26
patients, another 20 patients showedmental regres-
sion during active epilepsy.
Of the 32 treated patients, 3 had two to three
courses of treatment with steroids because of per-
sistent or recurrent seizures. We evaluated 36 treat-
ment courses. The type of therapy given differed
from one center to another. Thirteen treatment
courses with dexamathasone (doses of 0.5—5 mg/
kg/d and duration from 3 days to 8 months, continue
or in pulse therapy) were reported, ten with hydro-
cortisone (doses of 5—20 mg/kg/d and duration
from 4 weeks to 20 months), eight with prednisone
(doses of 0.3—3 mg/kg/d and duration from 7 days
to 24 months), one with methylprednisolone (dose
of 2 mg/kg/d and duration 2 months) and four with
ACTH (doses of 2—5 IU/kg/d and duration 3 weeks).
Duration of follow-up was between 6 months and 8
years with a mean follow-up period of 36 months.
Of the total of 36 treatment courses, 17 lead to a
clinically significant response and 19 did not. Thir-
teen (36%) patients were responders of whom nine
(25%) became seizure free and four (11%) had a
reduction in seizure frequency of more than 50%.
Another four (11%) had a reduction in seizure fre-
quency of less than 50%. The 17 patients with clini-
cally significant response are listed in Table 2. Of the
nine patients with seizure freedom during therapy,
three remained seizure free after long-term follow-
up (28 months to 4 years). Six of the nine relapsed,
one after 10 months and five during the first month
after stop steroids. However, four of the six patients
with relapse seizures still had a residual seizure
control of more than 50% at the end of follow-up
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Table 1 Patient characteristics.
Patient (age at onset) Seizures Frequency EEG MRI Mental status Regression? Diagnosis
1 8-yr male (6 yr) Atypical absences
disturbed sleep
Rare Awake spike-waves
bitemporal, ESES
Normal Mild MR regression ESES
2 9-mo female (1 d) Tonic, complex partial Daily Multifocal epileptic activity Normal Profound MR no regression Multifocal epilepsy of infancy
3 3-yr male (2 yr) Not observed Unknown Frequent epileptic activity a
ggravating during sleep
Unknown Profound MR no regression Quadriplegia, not responsive
4 5-yr male (4 yr) Simple partial complex partial Rare Awake left hemispheric
spike-waves, ESES
Normal Mild MR, NLD regression ESES
5 Same patient at age 6 Idem Idem Idem Idem Idem Idem
6 Same patient at age 7 Idem Idem Idem Idem Idem Idem
7 6-yr male (5 yr) Atypical absences, secondary
tonic—clonic
Daily Multifocal spikes left
hemispheric
Disturbance of grey
matter
Moderate MR regression Hepatic encephalopathy
8 6-yr female (2 yr) Absences, myoclonic, secondary
tonic—clonic
Several a week ESES Old haemorrhage
left thalamus
Severe MR regression ESES thalamic lesion
9 2-yr female (9 mo) Myoclonic, complex partial Several a day Left hemispheric alterations
generalising during sleep
A. cerebri media infarct Severe MR regression A. cerebri media infarct,
hemiplegia
10 15-mo female (6 mo) Absences, tonic, myoclonic Several a day Epileptic alterations
left posterior and
right temporal
Multifocal ischemic lesions Severe MR regression Encephalomalacie
11 6-yr male (3 yr) Absences, tonic—clonic, partial Several a month ESES Thalamic lesion
hydrocephaly
Severe MR regression Lesions post neonatal
haemorrhage, ESES
12 22-mo male (7 mo) Myoclonic Weekly Multifocal spikes and
spike-waves
Normal Severe MR regression Trisomia 21
13 8-yr male (12 d) Complex partial, secondary
generalized
Several a day Awake spike-waves
left-temporal,
ESES
Leucomalacia, thalamic
lesion
Moderate MR regression ESES, leucomalacia,
thalamic lesion
14 Same patient at age 9 Idem Idem idem Idem Idem Idem
15 5-yr female (3 yr) Complex partial, atypical
absences
Several a month Irregular generalized
spike-waves
Normal Mild MR no regression Multifocal epilepsy
16 10-yr male (9 yr) Complex partial, secondary
generalized
Several a week Right frontal nearly continue
spike-waves during sleep
Cortical—sub-cortical
atrophy
Mild MR regression Lesions post encephalitis
17 7-yr female (2 yr) Partial complex, secondary
generalized
Daily prolonged Multifocal spike-waves Hydrocephaly Severe MR regression Familial multifocal epilepsy,
hydrocephaly
18 4-yr female (14 mo) Myoclonic, tonic—clonic,
complex partial
Several a day Frequent bilateral frontal
spike-waves
Normal Moderate MR regression Lennox—Gastaut syndrome
19 6-mo female (1 d) Myoclonic Several a day Multifocal spike-waves Normal Profound MR regression Neurodegenerative disease
20 19-mo female (2 mo) Myoclonic, complex partial,
sec generalized
Daily Multifocal spike-waves Delayed myelinisation Severe MR regression Severe encephalopathy
21 3-yr male (3 yr) Atonic, clonic Several a day Sharp waves and slow
components bifrontal
Progressive demyelinisation Initial normal regression Ceroid lipofuscinose
22 3-yr male (2 yr) Atonic, tonic—clonic, partial Several a day Sharp waves and slow
components bifrontal
Normal Initial normal regression Lennox—Gastaut
syndrome, ataxia
23 11-yr male (10 yr) Myoclonic, complex partial Several a day Occipital nearly
continu spikes
Normal Initial normal regression Benign occipital epilepsy
24 12-mo female (5 mo) Complex partial,
prolonged
seizures
Several a week Prolonged spikes-waves
complexes
right hemisphere
Progressive cerebral
atrophia
Initial normal regression Alpers disease
25 9-mo male (1 d) Tonic—clonic Several a week Bilateral spike-waves Normal Moderate MR no regression Pyridoxine dependant seizures
26 3-yr female (18 mo) Tonic—clonic, partial Several a day Spikes and spike-waves Normal Moderate MR regression Myoclonic astatic epilepsy
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Table 1 (Continued )
Patient (age at onset) Seizures Frequency EEG MRI Mental status Regression? Diagnosis
27 9-yr male (5 yr) Complex partial Daily Awake discharges occipito-
temporal, ESES
Right ventricular
dilatation
Mild MR no regression ESES, lesions post ventricular
haemorrhage
28 Same patient at age 12 Idem Idem Idem Idem Mild MR regression Idem
29 9-yr female (2 yr) Complex partial Several a day Awake spikes right parieto-
occipital, ESES
Right insular infarct Moderate MR regression ESES
30 4-yr male (3 yr) Tonic—clonic, atonic,
complex partial
Daily Slow spike-wave complexes
left hemisphere
Normal Initial normal regression Intractable epilepsy
31 6-yr female (5 yr) Complex partial Daily Awake spikes right fronto-
temporal, ESES
Normal Initial normal regression Landau—Kleffner syndrome
32 5-yr male (3 mo) Complex partial Daily Awake multifocal spikes, ESES Multifocal cortical atrophia Mild MR regression ESES, lesions post encephalitis
33 4-yr female (8 mo) Complex partial Several a week Awake right hemispheric spikes,
ESES unilateral
Leucomalacia, hydrocephaly Severe MR regression ESES, leucomalacia, hydrocephaly
34 18-mo male (11 mo) Complex partial Several a day Frequent spike-waves right frontal Right A. cerebri media infarct Moderate MR regression A. cerebri media infarct,
hemiplegia
35 4-yr female (1 mo) Complex partial Daily Frequent spike-waves right
hemispheric
Right hemimegalencephaly Severe MR regression Right hemimegalencephaly
36 4-mo female (3 mo) Tonic Several a day Multifocal spike-waves Normal Severe MR no regression Severe encephalopathy
Previous AED Steroid therapy
(max. dose/d-duration)
Effect on
seizures
Effect on EEG Effect on cognition Side effects
1 CBZ-VPA-ESM-NZP-LTG
TOP-PHT-SLT
Hydrocortisone (10 mg/kg-7 mo) No No No Obesity Cushing
syndrome
2 PHB-PHT-CZP-VGB- CLB VPA Prednisone (1 mg/kg-7 d) No No No No
3 VGB-PHB-CZP-CBZ Prednisone (0.3 mg/kg-7 d) No No No No
4 VPA-CBZ-ESM-PB-PHT-LTG LZP-
CLB-immunoglobulins
Prednisone (3 mg/kg-25 d) No No Quieter behaviour Cushing syndrome
5 Idem + prednisone Prednisone (3 mg/kg-4 mo) No Less spike-waves
during daytime
No Cushing syndrome
6 Idem Dexamethasone (1 mg/kg-6 d) No No No No
7 PHB-LZP-PHT-CBZ-VGB CZP-SLT Dexamethasone (0.5 mg/kg-8 mo) <25% reduction No No Obesity
8 LTG-ESM-VGB-VPA-PHT CLB-CZP Prednisone (2mg/kg-6 we) No No More alert No
9 CBZ-VGB-LTG-PHB-CZP Dexamethasone (1 mg/kg-3 d) No No No No
10 PHB-VPA-VGB-CZP-TOP Dexamethasone (0.5 mg/kg-2  3 d) No No More alert No
11 ESM-VPA-CZP-LTG-CLB SLT-VGB-
PHT-PHB-TOP
Dexamethasone (0.5 mg/kg-3  3 d) No No More alert No
12 VGB-NZP-LTG-VPA Dexamethasone (0.5 mg/kg-3  3 d) No No No Infection
13 VPA-CBZ-VGB-LTG-TOP Dexamethasone (0.5 mg/kg-4  3 d) No No More alert, cognitive
improvement
Improved appetite
14 Idem + dexamethasone-GBP Dexamethasone (0.5 mg/kg-5  3 d) No No More alert, cognitive
improvement
Improved appetite
15 ESM-TOP Dexamethasone (0.5 mg/kg-2  3 d) No No No No
16 LZP-LTG-VPA Methylprednisolone (2 mg/kg-2 mo) 50—75% reduction Less spike-wave
activity
More alert Increased weight
17 LTG-VPA-CZP-TOP-CLB PHT Dexamethasone (0.5 mg/kg-4  3 d) >75% reduction Less spike-wave
activity
More alert Improved appetite
18 VPA-CBZ-LTG-TOP-CLB GBP-PHB Dexamethasone (0.5 mg/kg-3  3 d) <25% reduction No More alert Obesity
19 VPA-CLB-LEV-VGB-TOP Dexamethasone (5 mg/kg-2  3 d) No No No No
20 VGB-CBZ-VPA-TOP-CLB Dexamethasone (0.5 mg/kg-3 d) <25% reduction No More alert No
416
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Table 1 (Continued )
Previous AED Steroid therapy
(max. dose/d-duration)
Effect on
seizures
Effect on EEG Effect on cognition Side effects
21 VPA-NZP-LTG-CBZ-PHT Hydrocortisone (20 mg/kg-6 mo) 100% reduction Normalization No further regression Cushing syndrome,
irritation, sleep problems
22 VPA-CZP-VGB-LTG Hydrocortisone (20 mg/kg-6 mo) 100% reduction Normalization Improvement of ataxia Increased weight
23 CBZ-VPA-LTG-TOP Hydrocortisone (20 mg/kg-6 mo) 100% reduction Normalization Cognitive improvement Cushing syndrome
24 PHB-VPA-TOP-LMT-CZP Hydrocortisone (20 mg/kg-6 mo) 100% reduction Normalization More alert, cognitive
improvement
Increased weight
25 VPA-PHB-NZP Hydrocortisone (20 mg/kg-4 w) No Normalization No Femur fracture
26 VPA-PHB-ESM-NZP-PMD
homeopathy
Hydrocortisone (20 mg/kg-4 w) <25% reduction Improvement of
background activity
No Cushing, hypertension,
cardiac decompensation
27 CBZ-VPA-VGB-ESM-CLB PHT-
LTG-NZP-FLB
Hydrocortisone (5 mg/kg-20 mo) No No No Cushing syndrome,
increased weight
28 Idem + hydrocortisone-TOP CZP ACTH (2 IU/kg-3 w) 50—75% reduction Normalization EEG
during sleep
Cognitive and behavioral
improvement
No
29 CBZ-VPA-VGB-ESM-CLB TOP Hydrocortisone (5 mg/kg-20 mo) 100% reduction Normalization Cognitive improvement Hypertension,
obesity euphoria
30 VPA-CLB-ESM-CZP-PHT LMT-FLB Hydrocortisone (5 mg/kg-20 mo) No No No No
31 VPA-CLB Prednisone (2 mg/kg-11 mo) 100% reduction Normalization Cognitive and language
improvement
Obesity
32 PB-CBZ-CLB-VGB-VPA LTG-ESM Prednisone (2 mg/kg-20 mo) 100% reduction Normalization Cognitive and language
improvement
Obesity, infections,
hypertension, agression
33 CBZ-VGB-CLB-VPA-PHB FLB Prednisone (2 mg/kg-24 mo) 50—75% reduction No More alert Increased weight
34 CBZ-VGB-TOP-CZP-PHT
VPA-TGB-LTC
ACTH (5 IU/kg-3 w) 100% reduction Significant less spike-
wave activity
More alert No
35 VPA-CBZ-SLT-TOP-LMT ACTH (4 IU/kg-3 w) No No No Pneumonia
36 PHB-VPA-VGB-CZP-TOP ACTH (5 IU/kg-3 w) 100% reduction Clearing of epileptic
discharges
Mild improvement of
social contact
Hypokalaemia
Abbreviations: d, day; w, week; mo, month; yr, year; MR, mental retardation; NLD, nonverbal learning disorder; ESES, electrical status epilepticus in sleep; CBZ, carbamazepine; CLB,
clobazam; CZP, clonazepam; ESM, ethosuximide; FLB, felbamate; GBP, gabapentin; LEV, levetiracetam; LTG, lamotrigine; LZP, lorazepam; NZP, nitrazepam; PHB, phenobarbital; PHT,
phenytoin; PMD, primidone; SLT, sulthiame; TOP, topiramate; VGB, vigabatrin; VPA, valproate.
Ste
ro
id
s
in
ch
ild
h
o
o
d
e
p
ile
p
sy
417
Table 2 Follow-up responders.
Steroid therapy (max. dose) Total duration
steroid therapy
Total duration
follow-up
Relapse after
stop steroids?
Time interval
stop steroids—
relapse
Residual seizure
control after relapse
(% seizure reduction)
100% seizure reduction 21 Hydrocortisone (20 mg/kg) 6 mo 1 yr Yes <1 mo
22 Hydrocortisone (20 mg/kg) 6 mo 1 yr Yes <1 mo >50%
23 Hydrocortisone (20 mg/kg) 6 mo 4 yr No
24 Hydrocortisone (20 mg/kg) 6 mo 1 yr Yes <1 mo
29 Hydrocortisone (5 mg/kg) 20 mo 3 yr No
31 Prednisone (2 mg/kg) 11 mo 8 yr Yes <1 mo >50%
32 Prednisone (2mg/kg) 20 mo 6 yr Yes <1 mo >50%
34 ACTH (5 IU/kg) 3 w 28 mo No
36 ACTH (5 IU/kg) 3 w 6 yr Yes 10 mo >50%
>50% seizure reduction 16 Methylprednisolone (2 mg/kg) 2 mo 6 mo Yes 10 mo
17 Dexamethasone (0.5 mg/kg) 4  3 d 2 yr Yes 1 mo
28 ACTH (2 IU/kg) 3 w 16 mo No
33 Prednisone (2 mg/kg) 24 mo 6 yr No
<50% seizure reduction 7 Dexamethasone (0.5 mg/kg) 8 mo 3 yr No
18 Dexamethasone (0.5 mg/kg) 3  3 d 3 yr Yes 5 mo
20 Dexamethasone (0.5 mg/kg) 3 d 3 yr Yes 1 mo
26 Hydrocortisone (20 mg/kg) 4 w 1 yr Yes <1 mo
Abbreviations: d, day; w, week; mo, month; yr, year.
418 H. Verhelst et al.(1—8 year). Of the overall group of 13 responders, 8
had still a seizure frequency reduction of more than
50%, of which 3 were seizure free, at the end of the
study (1—8 year follow-up).
A positive effect on EEG recordings (normaliza-
tion, decrease in epileptiform activity, improve-
ment of background activity) was noticed in 15 of
the 36 treatment courses and in all of the 13
responders. In the 19 patients without reduction
in seizure frequency, improvement of EEG was only
noticed in 2. Cognitive or behavioral improvement
was noticed in 21 of the 36 treatment courses,
including all of the 13 responders. Of the four
patients with seizure frequency reduction less than
50%, two had a positive effect on cognition, and, of
the nineteen without reduction in seizure fre-
quency, six were more alert or had better behavior.
There was no difference in gender, mean age at
onset epilepsy, mean age at therapy, time interval
between first seizures and therapy, seizure type,
seizure frequency, findings on EEG or MRI, mental
status, presence of regression and etiological diag-
nosis between responders and non-responders. The
only factor that correlates with becoming seizure-
free was a longer duration of treatment, indepen-
dently of the type of steroid. Of the nine patients
who became seizure-free, two were treated with
ACTH, five with hydrocortisone and two with pre-
dnisone. The duration of hydrocortisone or predni-
sone therapy (including tapering off) was at least 6
months of continuous treatment in each of those
patients. Of the 19 patients without any clinically
significant response, 13 were treated for less than
4 weeks, 2 between 4 weeks and 6 months and only
4 longer than 6 months. Although, it should be
mentioned that in two patients steroid therapy
was stopped after 4 weeks because of lack of
response.
Side effects were noticed in 23 of the 36 treat-
ment courses and included obesity (6), increased
weight (5) or improved appetite (3), Cushing syn-
drome (7), behavioral disturbance (4), hypertension
(3), hypokalaemia (1), femur fracture (1) and car-
diac decompensation (1). Steroid therapy had to be
discontinued in one patient due to side effects. A
positive correlation between duration of treatment
and side effects was found. Of the 17 courses with
continuous treatment of more than 4 weeks, 16 had
side effects including the most severe side effects.
Of those who received less than 4 weeks continuous
steroid therapy (15), only 5 had milder side effects.
In those treated with ACTH (4), 2 were reported with
side effects. Of the 17 courses with continuous
treatment of more than 4 weeks, 10 were treated
with hydrocortisone, 6 with prednisone or methyl-
prednisolone and 1 with dexamethasone. No corre-lation was seen between type of steroid and number
and severity of side effects.Discussion
Steroids and adrenocorticotrophic hormone have
been used in the treatment of infantile spasms for
several years3. The option of treating with ACTH or
steroids is still the subject of ongoing contro-
versy,4—8 and not only the type of steroid but also
its dosage, timing and duration remain undefined.9
The use of steroids in the treatment of epilepsy
beyond infantile spasms has been limited to only a
few studies.6,10—12 Good response to ACTH was
described in Ohtahara syndrome13 and in Len-
nox—Gastaut syndrome.14 Steroids or other immu-
nomodulating therapies are reported to be
effective in Landau—Kleffner syndrome and in
electrical status epilepticus in sleep.15—19 Snead
et al. described their experience in 64 children
with intractable epilepsy–—other than infantile
spasms–—treated with either ACTH or prednisone.
Most patients had myoclonic seizures. Treatment
was successful in 74% of those treated with ACTH
and in none of those treated with prednisone
(3 mg/kg/d for 12 weeks). This finding made the
author assume that the mechanism of action was
extra-adrenal and that ACTH had a direct effect on
neuronal function.6 Hasaerts et al. presented a
retrospective study of 32 children with secondary
generalized epilepsy treated with hydrocortisone
5 mg/kg/d for 1 month, tapered during at least 6
months. Half of the children exhibited significant
reduction of seizure frequency and in 2/3 cognitive
abilities improved. Results were better in tonic and
tonic—clonic seizures than in absences.10 Sinclair
reported his experience with prednisone (1 mg/
kg/d for 12 weeks–—6 weeks daily and 6 weeks
on alternate days) in 28 children older than 1 year
with intractable epilepsy. Thirteen patients (46%)
became seizure free and another ten (36%) had a
significant decrease in seizure frequency. Best out-
comes were seen in absence seizures and Lennox—
Gastaut syndrome.11
In our study, a retrospective assessment was made
of 36 courses of steroid treatment in a heterogeneous
pediatricpopulationwith intractableepilepsy.Due to
the contribution of threedifferent centers anddue to
the retrospective character of this study, different
types of steroids in different dosages and durations
were given. Of the 36 courses of treatment, 17 (47%)
showed a clinically significant response of whom 9
(25%) became seizure free, 4 (11%) had a seizure
reductionof>50%and4 (11%)hada seizure reduction
of<50%.Moreover, after stop steroid therapy, 8 (22%)
Steroids in childhood epilepsy 419remained good responders with 3 (8%) still seizure
free and 5 (14%) having a reduction in seizure fre-
quency of>50% (follow-up 1—8 year). EEG, cognitive
and behavioral improvement was observed in all
responders.We foundnocorrelationbetween seizure
type and outcome possibly due to the heterogeneity
of the samplegroup.Alsonocorrelationcouldbe seen
between type of steroid used and effect on epilepsy
or cognition. The only factor that seems to correlate
with becoming seizure free was longer duration of
treatment, which conforms to findings in literature.
Good results of steroid therapy in the study of
Hasaerts et al.10 and Sinclair11 were also obtained
with prolonged therapy of respectively 6 months and
12 weeks.Figure 1 Decision tree when dealing wiOn the other hand, we found more frequent and
more severe side effects in patients receiving ster-
oid therapy for more than 4 weeks. During 16/17
courses (94%) with treatment duration of more than
4 weeks, side effects were reported. In one patient
with cardiac decompensation, therapy had to be
stopped. Hasaerts et al. reported side effects in
56%10 and Sinclair in 28%.11
The anti-seizure mechanism of action of corticos-
teroids or ACTH is unknown. ACTHhas both endocrine
and neuromodulatory properties. Firstly, ACTH, as a
neuropeptide, may have anti-convulsive properties
by itself.9 Secondly, ACTH may act by stimulation of
glucocorticoid synthesis. Glucocorticoids are thought
to interactwithcentralnervous systemsteroid recep-th children with intractable epilepsy.
420 H. Verhelst et al.tors that act as transcriptional regulators20 and to
influence voltage-dependent calcium channels.21
Thirdly, ACTH may exert a positive effect by neuro-
steroid synthesis in glial cells and neurons.
ACTH induces the synthesis of deoxycorticosterone
(DOC) a precursor of dihydrodeoxy-corticosterone
(DHDOC) and tetrahydrodeoxy-corticosterone
(THDOC).DHDOCandTHDOCareboth allostericmod-
ulators of GABAA receptors.
22 Down regulation of
corticotropin releasing hormone (CRH) expression
may also be of importance, given the proconvulsant
activity of CRH in the immature brain.23 Last but not
least, ACTH as well as corticosteroids have immuno-
modulatory properties. Immunomodulation has been
suggested as the mechanism of action in Landau—
Kleffner syndromeandESES,whichare assumed tobe
autoimmune diseases of the brain.19 For the same
reason high-dose steroids are used in Rasmussen’s
encephalitis.24
Endogenous steroid hormones, mainly synthe-
sized in the adrenal glands, the gonads and the
feto-placental unit, can easily cross the blood—
brain barrier due to their high lipid solubility and
act as neuroactive steroids. Estrogens exacerbate
seizures whereas progesterone is protective. The
physiological premenstrual decrease of progester-
one and its metabolites may cause catamenial sei-
zures as well as psychic changes in the premenstrual
period.25 In vivo progesterone may be converted
into highly neuroactive compounds, in particular
allopregnanolone. Allopregnanolone is a very potent
positive-allosteric modulator of the GABAA receptor
complex.26 Interestingly the human hippocampus is
equipped with enzymes that are necessary for sex
steroid formation and metabolism. Cholesterol can
be converted to the potent neurosteroid allopreg-
nanolone in human hippocampus, temporal lobe and
other human brain regions.27
Naturally occurring neuroactive steroids undergo
rapid biotransformation upon exogenous adminis-
tration. Ganaxolone, a 3-beta-methylated synthetic
analogue was designed to overcome this pharmaco-
kinetic limitation.28 Ganaxolone is as potent as
allopregnanolone in modulating GABAA receptors
but has no hormonal function. In humans, ganaxo-
lone showed a promising pharmacokinetic profile
and was well tolerated in a trial with 96 healthy
volunteers.29 The steroid proved to be well toler-
ated and effective in the first clinical studies with
epilepsy patients.30—32 Double-blind randomized
studies are necessary to establish the future role
for ganaxolone in clinical practice.
As practical instrument when dealing with chil-
dren with intractable epilepsy, we tried to make a
decision tree (Fig. 1). Since no class I evidence is
available about this topic due to lack of prospective,controlled, randomized studies, this decision tree is
empiric and meanly based on our own clinical
experience. Alternative therapies are used when
children do not respond to classical anti-epileptic
drugs, are no good candidates for epilepsy surgery
and when seizures or EEG disturbances are frequent
disabling daily live. Vagus nerve stimulation is a
palliative therapy only used when ‘medicinal’ ther-
apy failed including immunotherapy and/or keto-
genic diet. Ketogenic diet is preferable in some
specific metabolic disorders like pyruvate dehydro-
genase (PDH) deficiency33 or Glut-1 deficiency syn-
drome34 and in some patients with predominant
seizure types other than complex partial.35 Immu-
notherapy is classically used in West syndrome.4—8 It
is also described, with less evidence, in Lennox—
Gastaut syndrome,14 Landau—Kleffner syndrome
and electrical status epilepticus during sleep,15—19
Rasmussen encephalitis24 and Ohtahara syndrome.13
In our experience, children with cognitive regres-
sion and behavior problems due to their epilepsy are
good candidates too for immunotherapy. When
starting immunotherapy, a choice has to be made
between intravenous immunoglobulins and steroids.
Since in our country intravenous immunoglobulins
are expensive and not reimbursed in the indication
epilepsy, we first go for a trial with steroids. Known
contraindications for steroid therapy are severe
concurrent infections, hypertension, diabetes,
osteoporosis and growth retardation. Since there
are, nor in literature, neither in our own experi-
ence, no significant arguments in favor of ACTH
intramuscular above oral administration of steroids
we propose to treat orally, avoiding in this way
discomfort and hospitalization. A possible sugges-
tion is a trial of 4 weeks with hydrocortisone 10 mg/
kg/d.We prefer hydrocortisone above other steroids
because of less mineralocorticoid effect. A 4-week
trial is long enough to evaluate possible positive
effect and is short enough tominimalize side effects.
If not effective, a fast tapering should follow in order
to prevent severe side effects. When effective, a
more gentle decrease in dose, over a period of
months to even years, is necessary to maintain the
positive effect. Rate of tapering can be influenced by
possible side effects or relapses of epilepsy.Conclusion
Our study confirms previous reports of the effec-
tiveness of adjunctive steroid treatment for chil-
dren with intractable epilepsy. Side effects,
especially of prolonged therapy, remain an impor-
tant concern.
Steroids in childhood epilepsy 421References
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